Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
BrightSpring Health Services (BTSG) Reports +26.4% Revenue Growth in Q3 2026

BrightSpring Health Services (BTSG) Reports +26.4% Revenue Growth in Q3 2026

Key Takeaways

  • Net revenue rose 26.4% year over year to $4.21 billion, ahead of the roughly $3.87 billion consensus estimate.
  • Adjusted EPS (earnings per share) of $0.54 topped the $0.47 analyst consensus by about 14.7%.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $228 million grew 42% year over year and beat expectations.
  • Management raised full-year 2026 revenue and Adjusted EBITDA guidance across both business segments.
  • Pharmacy Solutions revenue grew 26% and Provider Services revenue grew 31% year over year.
  • Leverage declined to 1.79x, reflecting stronger cash generation and balance-sheet flexibility.
  • For more on BTSG's Major News, Today's Price Move, Price Targets, and Forecasts, explore the dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

BrightSpring Health Services is a leading provider of home- and community-based health services for complex, medically vulnerable populations, serving roughly 500,000 patients daily across all 50 states. The company's two operating segments — Pharmacy Solutions and Provider Services — sit at the center of healthcare's shift toward lower-cost, patient-preferred care settings. This quarterly earnings report matters because it tests whether BTSG can sustain the double-digit growth it has delivered since its 2024 initial public offering while absorbing a major strategic change: the March 2026 divestiture of its Community Living business. Investors also watch closely for evidence that specialty and infusion pharmacy momentum, driven by limited distribution drug launches, can offset reimbursement pressures elsewhere in the business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

BrightSpring reported third quarter 2026 net revenue of $4.21 billion, up 26.4% from $3.33 billion in the prior-year period and above the analyst consensus estimate of roughly $3.87 billion. Gross profit increased 32.3% to $519 million, while net income from continuing operations reached $101 million, compared with $38 million a year earlier.

Adjusted EBITDA climbed 42.0% to $228 million, exceeding the approximately $214.8 million consensus. Adjusted EPS came in at $0.54, comfortably ahead of the $0.47 estimate. By segment, Pharmacy Solutions revenue rose 26% to $3.73 billion, and Provider Services revenue rose 31% to $481 million. The company also reduced its leverage ratio to 1.79x as of September 30, 2026, from 2.15x at the end of the prior quarter.

Management raised full-year 2026 guidance, now projecting revenue of $15.9 billion to $16.125 billion and Adjusted EBITDA of $850 million to $860 million. From what I see, the broad-based improvement across segments points to solid operational execution.

Market Reaction and Investor Sentiment

Shares of BTSG rose sharply in the wake of the report, with the stock surging roughly 7.1% to about $64.50, according to market data compiled after the announcement. The positive reaction reflected a clean beat across the board — revenue, Adjusted EPS, and Adjusted EBITDA all landed above consensus — combined with a guidance increase that suggests momentum is extending into the fourth quarter and beyond.

Investor sentiment was further supported by broad-based segment strength. Pharmacy Solutions benefited from specialty and infusion script growth and a growing portfolio of limited distribution drug (LDD) launches, while Provider Services gained from strong home health census and the contribution of recently acquired Amedisys and LHC branches. The combination of top-line growth and margin improvement reinforced confidence in the company's execution.

Forward Outlook and Key Factors to Monitor

Following this quarter's results, investors will focus on whether BTSG can sustain its growth trajectory into 2027. Management reiterated its expectation for at least 15% to 20% organic Adjusted EBITDA growth next year, though now off a larger 2026 base. Sustaining that pace will depend on continued specialty and infusion expansion, an active pipeline of new limited distribution drug launches, and successful integration of acquired branches.

Several factors warrant close attention. In Pharmacy Solutions, the Home and Community Pharmacy business is absorbing an estimated $200 million full-year revenue impact from the Inflation Reduction Act (IRA), a federal law affecting drug pricing, along with the company's exit from uneconomic customers. Underlying growth in that line has nevertheless improved through the year, and management expects continued progress.

On the Provider Services side, home health census growth, de novo expansion, and value-based care programs — including a new LEAD ACO (Accountable Care Organization) Medicare program starting in January — represent key catalysts. Margin trends, clinician retention, and the pace of cash-flow conversion will also remain central to the investment thesis as the company balances growth with disciplined capital deployment. I'm watching this closely as the company moves into the new year.

Using Tickeron’s AI Tools in Practice

In my own research process, I often turn to Tickeron’s AI Screener to quickly filter healthcare names and compare fundamentals like revenue growth and EBITDA margins against peers. It helps surface comparable opportunities without spending hours on manual screens, which is especially useful when tracking names like BTSG that operate in evolving sectors. This kind of tool complements traditional analysis by highlighting technical patterns and AI-driven signals that might otherwise go unnoticed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BTSG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BTSG's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for BTSG moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 20 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BTSG as a result. In 29 of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for BTSG turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 23 similar instances when the indicator turned negative. In 15 of the 23 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BTSG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

BTSG moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where BTSG advanced for three days, in 173 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

BTSG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 158 of 176 cases where BTSG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. BTSG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.485) is normal, around the industry mean (4.523). P/E Ratio (37.725) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.915) is also within normal values, averaging (6.105).

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTSG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
805 N. Whittington Parkway
Phone
+1 502 394-2100
Employees
23500
Web
https://www.brightspringhealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.